trial

An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia

NCTId NCT01894984
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Terminated
Enrollment 640 (actual)
Sponsored by Xian-Janssen Pharmaceutical Ltd.
Primary completion 2009-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
640 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2007-01
Primary completion
2009-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
RisperidoneOral atypical anti-psychotic

Sponsors

Xian-Janssen Pharmaceutical Ltd.Lead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
640
Phase
NA
Primary Completion Date
2009-12
Status
TERMINATED
relationships
The graph out of here
drug
Risperidone
drug
Oral atypical anti-psychotic
drug
lead_sponsor
Xian-Janssen Pharmaceutical Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication